Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lyra Therapeutics stock | $7.18

Learn how to easily invest in Lyra Therapeutics stock.

Lyra Therapeutics, Inc is a biotechnology business based in the US. Lyra Therapeutics shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Lyra Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Lyra Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LYRA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Lyra Therapeutics stock price (NASDAQ: LYRA)

Use our graph to track the performance of LYRA stocks over time.

Lyra Therapeutics shares at a glance

Information last updated 2021-07-28.
Latest market close$7.18
52-week range$6.18 - $15.83
50-day moving average $8.06
200-day moving average $10.33
Wall St. target price$26.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Lyra Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyra Therapeutics price performance over time

Historical closes compared with the close of $7.18 from 2021-05-28

1 week (2021-07-25) N/A
1 month (2021-07-02) -12.55%
3 months (2021-05-05) -14.93%
6 months (2021-02-01) N/A
1 year (2020-08-01) N/A
2 years (2019-08-01) N/A
3 years (2018-08-01) N/A
5 years (2016-08-01) N/A

Lyra Therapeutics financials

Gross profit TTM $0
Return on assets TTM -28.36%
Return on equity TTM -50.9%
Profit margin 0%
Book value $5.21
Market capitalisation $86.2 million

TTM: trailing 12 months

Shorting Lyra Therapeutics shares

There are currently 239,441 Lyra Therapeutics shares held short by investors – that's known as Lyra Therapeutics's "short interest". This figure is 0.3% up from 238,665 last month.

There are a few different ways that this level of interest in shorting Lyra Therapeutics shares can be evaluated.

Lyra Therapeutics's "short interest ratio" (SIR)

Lyra Therapeutics's "short interest ratio" (SIR) is the quantity of Lyra Therapeutics shares currently shorted divided by the average quantity of Lyra Therapeutics shares traded daily (recently around 145115.75757576). Lyra Therapeutics's SIR currently stands at 1.65. In other words for every 100,000 Lyra Therapeutics shares traded daily on the market, roughly 1650 shares are currently held short.

However Lyra Therapeutics's short interest can also be evaluated against the total number of Lyra Therapeutics shares, or, against the total number of tradable Lyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lyra Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Lyra Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0456% of the tradable shares (for every 100,000 tradable Lyra Therapeutics shares, roughly 46 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lyra Therapeutics.

Find out more about how you can short Lyra Therapeutics stock.

Lyra Therapeutics share dividends

We're not expecting Lyra Therapeutics to pay a dividend over the next 12 months.

Lyra Therapeutics overview

Lyra Therapeutics, Inc. , a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.

Frequently asked questions

What percentage of Lyra Therapeutics is owned by insiders or institutions?
Currently 1.412% of Lyra Therapeutics shares are held by insiders and 77.815% by institutions.
How many people work for Lyra Therapeutics?
Latest data suggests 43 work at Lyra Therapeutics.
When does the fiscal year end for Lyra Therapeutics?
Lyra Therapeutics's fiscal year ends in December.
Where is Lyra Therapeutics based?
Lyra Therapeutics's address is: 480 Arsenal Way, Watertown, MA, United States, 02472
What is Lyra Therapeutics's ISIN number?
Lyra Therapeutics's international securities identification number is: US55234L1052
What is Lyra Therapeutics's CUSIP number?
Lyra Therapeutics's Committee on Uniform Securities Identification Procedures number is: 55234L105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site